Hansa Biopharma and Medison Pharma announce positive reimbursement decision in Poland for Idefirix® in highly sensitized kidney transplant patients

  • Idefirix® (imlifidase) becomes the first and only product reimbursed for the desensitization of highly sensitized patients waiting for a kidney transplant in Poland
  • Reimbursement follows the inclusion of Idefirix® on the shortlist for exceptional innovative treatments with special funding   
  • The reimbursement decision provides highly sensitized patients in Poland access to Idefirix® to enable kidney transplantation from September 1st, 2022

LUND, Sweden and PETACH TIKVAH, IsraelAug. 22, 2022 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, and its partner Medison Pharma, "Medison", a global pharmaceutical company focused on providing access to highly innovative therapies for patients in international markets, today announced that the Polish Ministry of Health has agreed to include Idefirix® on its reimbursement list for desensitization of highly sensitized patients prior to kidney transplantation. This decision follows last year's inclusion of Idefirix® onto the "List of Technologies with a high level of innovation" of the Polish Medical Fund. Based on the decision to grant reimbursement, Idefirix® will be fully financed and available to patients who qualify for a newly established drug program run by multiple transplant centres in Poland from September 1st 2022.

For the complete press release click here.